Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07222748

A Phase 3, Randomized, Double-blind, Comparator- and Placebo-controlled Study to Evaluate the Safety and Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

Led by TLC Biopharmaceuticals, Inc. · Updated on 2025-12-02

300

Participants Needed

4

Research Sites

4 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are conducting a Phase 3, randomized, double-blind study to evaluate the pain relief and safety of TLC590 in adults after bunionectomy surgery. The study compares TLC590 with liposomal bupivacaine and a saline placebo to assess their effects on postoperative pain management. This research is sponsored by TLC Biopharmaceuticals, Inc. and focuses on pain following a specific foot surgery called bunionectomy. Participants will receive one of three treatments: TLC590 (a ropivacaine extended-release injectable suspension), liposomal bupivacaine, or a saline placebo. These treatments will be given by local infiltration during the surgery. The study aims to monitor pain relief and opioid use during the first 72 hours after surgery to compare the effects of these treatments. During the trial, participants will have their pain intensity measured using the Numeric Rating Scale over 72 hours after surgery. Researchers will also track opioid use and other safety measures. The study involves random assignment to treatment groups and triple masking to ensure unbiased results. The total participation duration includes the immediate 72-hour postoperative period with ongoing safety assessments.

CONDITIONS

Brief Title

A Study of TLC590 for Postsurgical Pain Following Bunionectomy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able and willing to provide written informed consent.
  • Male or female aged 18 years or older.
  • Scheduled for primary unilateral, transpositional first metatarsal bunionectomy with osteotomy and internal fixation under regional anesthesia.
  • ASA Physical Status Classification of 1 or 2.
  • Male subjects must be sterile or agree to use reliable birth control or abstain from sexual activity.
  • Female subjects must not be pregnant, lactating, or planning pregnancy, or agree to use highly effective birth control.
  • Body mass index between greater than 18 and 39 kg/m2, with a minimum weight of 50 kg.
Not Eligible

You will not qualify if you...

  • Abnormal clinical laboratory test values.
  • Clinically significant abnormal 12-lead ECG.
  • History of orthostatic hypotension, syncope, or other syncopal attacks.
  • Significant renal, hepatic, gastrointestinal, cardiovascular, metabolic, neurologic, psychiatric, or other conditions unsuitable for study participation.
  • History of seizures or use of anticonvulsants.
  • History of cardiac arrhythmia or use of Class III antiarrhythmic drugs.
  • History of sleep apnea or use of at-home CPAP treatment.
  • Hypersensitivity to ropivacaine, bupivacaine, amide-type local anesthetics, or study medications.
  • Severe or refractory postoperative nausea and vomiting from other causes.
  • History of suicidal attempt or behavior.
  • History or positive test for HIV, HCV, or HBV.
  • History or current substance or alcohol abuse.
  • Positive urine drug or alcohol breath test.
  • Pre-existing acute or chronic painful conditions that may affect pain assessments.
  • Daily opioid use over 4 days per week within 6 months.
  • Daily analgesic use over 4 days per week for chronic pain.
  • Receiving oxygen therapy.
  • Use of pre-specified medications before surgery as defined.
  • Malignancy in past 2 years except certain skin or cervical cancers.
  • Personal or family history of malignant hyperthermia.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 72 hours

Participants receive TLC590, Liposomal Bupivacaine, or Saline Placebo following bunionectomy to manage postsurgical pain.

1 treatment visit during surgery and monitoring through 72 hours postsurgery

Trial Site Locations

Total: 4 locations

1

Clinical Pharmacology of Miami

Miami, Florida, United States, 33172

Not Yet Recruiting

2

First Surgical Hospital

Bellaire, Texas, United States, 77401

Actively Recruiting

3

Memorial Hermann Village

Houston, Texas, United States, 77043

Actively Recruiting

4

Endeavor Clinical Trials

San Antonio, Texas, United States, 78240

Not Yet Recruiting

Loading map...

Research Team

J

Jack Chang

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Similar Trials

A Clinical Follow-up Study on the Efficacy of Thumbtack Need...

Postoperative Complications

Actively Recruiting

2 locations

Continuous Post-operative Lidocaine Infusion Following Major...

Postoperative Delirium

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here